Skip to main content
Back to companies
Cambridge, Massachusetts, United StatesFounded 202021+ employeesPrivate
$37.4M raisedSeries A· last: series a (May 2024)· 5 rounds

Nabla Bio is building an end-to-end antibody creation platform. Nabla Bio is applying natural language processing algorithms to amino acids generating a predictive “biophysical fingerprint” for 1 million antibodies in a single step.

Founders

Skip jobs list

Open Positions at Nabla Bio (14 Jobs)

14 open · 5 remote · 3 filled

Showing 14 jobs